A low level of CD16pos monocytes in SARS-CoV-2 infected patients is a marker of severity
Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), a...
Saved in:
Published in | Clinical chemistry and laboratory medicine Vol. 59; no. 7; pp. 1315 - 1322 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
De Gruyter
25.06.2021
Walter De Gruyter & Company |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.In the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3–0.7×109/L) and (0.015–0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).Quantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients. |
---|---|
AbstractList | Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.In the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3–0.7×109/L) and (0.015–0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).Quantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients. Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.OBJECTIVESSevere forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high levels of cytokines. Human monocytes are divided into three major populations: conventional (CD14posCD16neg), non-classical (CD14dimCD16pos), and intermediate (CD14posCD16pos) monocytes. The aim of this study was to analyze whether the distribution of conventional (CD16neg) and CD16pos monocytes is different in patients with COVID-19 and whether the variations could be predictive of the outcome of the disease.We performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.METHODSWe performed a prospective study on 390 consecutive patients referred to the Emergency Unit, with a proven diagnosis of SARS-CoV 2 infection by RT-PCR. Using the CytoDiff™ reagent, an automated routine leukocyte differential, we quantified CD16neg and CD16pos monocytes.In the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3-0.7×109/L) and (0.015-0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).RESULTSIn the entire population, median CD16neg and CD16pos monocyte levels (0.398 and 0.054×109/L, respectively) were in the normal range [(0.3-0.7×109/L) and (0.015-0.065×109/L), respectively], but the 35 patients in the intensive care unit (ICU) had a significantly (p<0.001) lower CD16pos monocyte count (0.018 × 109/L) in comparison to the 70 patients who were discharged (0.064 × 109/L) or were hospitalized in conventional units (0.058 × 109/L). By ROC curve analysis, the ratio [absolute neutrophil count/CD16pos monocyte count] was highly discriminant to identify patients requiring ICU hospitalization: with a cut-off 193.1, the sensitivity and the specificity were 74.3 and 81.8%, respectively (area under the curve=0.817).Quantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients.CONCLUSIONSQuantification of CD16pos monocytes and the ratio [absolute neutrophil count/CD16pos monocyte count] could constitute a marker of the severity of disease in COVID-19 patients. |
Author | Goubeau, Laurie Cerf, Charles Habarou, Florence Ackermann, Felix Zuber, Benjamin Delcominette, Frédérique Roumier, Mathilde Farfour, Eric Vasse, Marc Jolly, Emilie Pascreau, Tiffany Ballester, Marie-Christine |
Author_xml | – sequence: 1 givenname: Marc orcidid: 0000-0002-8784-7209 surname: Vasse fullname: Vasse, Marc email: m.vasse@hopital-foch.org organization: UMRS-1176, Le Kremlin-Bicêtre, France – sequence: 2 givenname: Benjamin surname: Zuber fullname: Zuber, Benjamin organization: Intensive Care Unit, Foch Hospital, Suresnes, France – sequence: 3 givenname: Laurie surname: Goubeau fullname: Goubeau, Laurie organization: Biology Department, Foch Hospital, Suresnes, France – sequence: 4 givenname: Marie-Christine surname: Ballester fullname: Ballester, Marie-Christine organization: Emergency Unit, Foch Hospital, Suresnes, France – sequence: 5 givenname: Mathilde surname: Roumier fullname: Roumier, Mathilde organization: Internal Medicine Department, Foch Hospital, Suresnes, France – sequence: 6 givenname: Frédérique surname: Delcominette fullname: Delcominette, Frédérique organization: Biology Department, Foch Hospital, Suresnes, France – sequence: 7 givenname: Florence surname: Habarou fullname: Habarou, Florence organization: Biology Department, Foch Hospital, Suresnes, France – sequence: 8 givenname: Emilie surname: Jolly fullname: Jolly, Emilie organization: Biology Department, Foch Hospital, Suresnes, France – sequence: 9 givenname: Felix surname: Ackermann fullname: Ackermann, Felix organization: Internal Medicine Department, Foch Hospital, Suresnes, France – sequence: 10 givenname: Charles surname: Cerf fullname: Cerf, Charles organization: Intensive Care Unit, Foch Hospital, Suresnes, France – sequence: 11 givenname: Eric orcidid: 0000-0003-3243-8018 surname: Farfour fullname: Farfour, Eric organization: Biology Department, Foch Hospital, Suresnes, France – sequence: 12 givenname: Tiffany surname: Pascreau fullname: Pascreau, Tiffany organization: UMRS-1176, Le Kremlin-Bicêtre, France |
BookMark | eNpdkE1Lw0AQhhepYFu9el7w4mV1Zz_ycfBQ4icUBKviLWySiaQm2ZrdWPrvTawgeHpnmIeX4ZmRSWtbJOQU-AVo0Jd5XjdMcMEZRBwOyBSUDJmSEiY_s2JBIOCIzJxbcw5aq3BK3ha0tlta4xfW1JY0uYZgYx1tbGvznUdHq5auFk8rlthXJoatxNxjQTfGV9j64e6ooY3pPrAbC9zQ1FV-d0wOS1M7PPnNOXm5vXlO7tny8e4hWSzZRijumYjLEjJEDCXXGTfhmKIoszgAU4BAU_A8ioQKELM4M1EmIp4bDVJHEZco5-R837vp7GePzqdN5XKsa9Oi7V0qVAyxAh7yAT37h65t37XDd6nQSoDgKpADdbWntqb22BX43vWDiO4PBp6OwtNReDoKT0fhOg5Bgpbf3G11xA |
ContentType | Journal Article |
Copyright | 2021 Walter de Gruyter GmbH, Berlin/Boston 2021 Walter de Gruyter GmbH, Berlin/Boston. |
Copyright_xml | – notice: 2021 Walter de Gruyter GmbH, Berlin/Boston – notice: 2021 Walter de Gruyter GmbH, Berlin/Boston. |
DBID | 7QO 7T7 7TK 7U7 8FD C1K FR3 P64 7X8 |
DOI | 10.1515/cclm-2020-1801 |
DatabaseName | Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Biotechnology Research Abstracts MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry |
EISSN | 1437-4331 |
EndPage | 1322 |
ExternalDocumentID | 10_1515_cclm_2020_18015971315 |
GroupedDBID | --- 0R~ 0~D 29B 354 36B 4.4 53G 5GY 5RE AAAEU AABBZ AAFPC AAGVJ AAILP AALGR AAOQK AAOWA AAPJK AAQCX AARRE AASQH AAWFC AAXCG ABAOT ABAQN ABDRH ABFKT ABFQV ABIQR ABJNI ABLJU ABMIY ABPLS ABRDF ABUVI ABWLS ABXMZ ABYBW ACDEB ACEFL ACGFS ACIWK ACPMA ACPRK ACUND ACYCL ACZBO ADDWE ADEQT ADGQD ADGYE ADOZN AECWL AEDGQ AEGVQ AEICA AEJTT AENEX AEQDQ AERZL AEXIE AFBAA AFBDD AFBQV AFCXV AFGDO AFQUK AFRAH AFYRI AGBEV AHOVO AHVWV AHXUK AIERV AIWOI AJATJ AJHHK AKXKS ALMA_UNASSIGNED_HOLDINGS ALUKF ALYBR ASYPN BAKPI BBCWN BCIFA CGQUA CS3 DU5 EBS EMOBN F5P HZ~ IY9 KDIRW N9A O9- OBC OBS OEB OES OHH P2P PQQKQ QD8 RDG SA. SLJYH TEORI UK5 WTRAM 7QO 7T7 7TK 7U7 8FD ADNPR C1K FR3 P64 7X8 |
ID | FETCH-LOGICAL-p240t-29ff1beee7305b0a773052dfb961ad12ead0c88246eeb9ba8b280ca51358803e3 |
ISSN | 1434-6621 1437-4331 |
IngestDate | Fri Jul 11 11:22:49 EDT 2025 Wed Aug 13 08:58:45 EDT 2025 Thu Jul 10 10:36:56 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p240t-29ff1beee7305b0a773052dfb961ad12ead0c88246eeb9ba8b280ca51358803e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-8784-7209 0000-0003-3243-8018 |
OpenAccessLink | https://www.degruyter.com/document/doi/10.1515/cclm-2020-1801/pdf?licenseType=free |
PQID | 2542120463 |
PQPubID | 105421 |
PageCount | 08 |
ParticipantIDs | proquest_miscellaneous_2491941070 proquest_journals_2542120463 walterdegruyter_journals_10_1515_cclm_2020_18015971315 |
PublicationCentury | 2000 |
PublicationDate | 2021-06-25 |
PublicationDateYYYYMMDD | 2021-06-25 |
PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-25 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin |
PublicationTitle | Clinical chemistry and laboratory medicine |
PublicationYear | 2021 |
Publisher | De Gruyter Walter De Gruyter & Company |
Publisher_xml | – name: De Gruyter – name: Walter De Gruyter & Company |
SSID | ssj0015547 |
Score | 2.352024 |
Snippet | Severe forms of coronavirus disease 2019 (COVID-19) are characterized by an excessive production of inflammatory cytokines. Activated monocytes secrete high... |
SourceID | proquest walterdegruyter |
SourceType | Aggregation Database Publisher |
StartPage | 1315 |
SubjectTerms | CD16 Coronaviruses COVID-19 Cytokines Inflammation intensive care unit Leukocytes Leukocytes (neutrophilic) Markers Monocytes Neutrophils Polymerase chain reaction Reagents Severe acute respiratory syndrome coronavirus 2 Viral diseases |
Title | A low level of CD16pos monocytes in SARS-CoV-2 infected patients is a marker of severity |
URI | https://www.degruyter.com/doi/10.1515/cclm-2020-1801 https://www.proquest.com/docview/2542120463 https://www.proquest.com/docview/2491941070 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJgEvEwwQhYGMxFvl0Ti35jErYxNSeWBb1bfKdhxU1CbTmmgaP47fxjmxnbTVhGAvaZXUTurz5Vx8boR8zGQSqDgWLNdSMOB-wAcFD5jmIY9BPHCe4Yb-5Ft0fhV8nYWzXu_3RtRSXclj9evevJKHUBXOAV0xS_Y_KNtOCifgO9AXjkBhOP4TjdPBsrwdLDHupwmr-OxF1yV2tylKdVc1oVaDi_T7BRuXU8Zt4BVomLaY6hq7mYvBCiN0GmcBSEmNzew2NdaxS51UrjVc42-w4EEP_a57fgr6uLZ5QKrdmK6lAceJLn6K1aLF5FkJV0TtcrQXnZcfu7y4viETNOmZqYTgbmX3KngTU2Xymk3ACQD_pr5zcceG4wZ-wKLIpEkfa3cu7lK5LJu2hcMNHOMNnuv5JiHUym80r--VDWFTRkOp5QpAxNGjbbdRtopw7wjHNmQRjSWYYY7j5zh-juPBHMPbPyL7HMwU4LP76dnJ6bT1Y4Gy1rT3cX_Slg2FiT5tP8iWgXNw24RKZPqHWa0NjefyGTmwpgpNDe6ek54uDsmTsYPBIXk8sZR_QWYpBSjSBoq0zKmFIm2hSBcF7aBIHRSpgyJdrKmgBoo4gYPiS3L15fRyfM5s0w52DcphxXiS557UWoPoCOVQxPjJs1wmkScyjwPnGiow64JIa5lIMZJ8NFQi9PwQRImv_VdkrygL_ZrQoVJ5NoqyaCTzIMqVFFmutZdJ7cdgqId9cuTWbG7fyvWchxjjgHXw-uRDexkWBh1hotBlDb8JEi8JPJB2fRLtrHU3018p_uahA9-Sp92bcUT2qptavwO9tpLvLXj-AF0ho24 |
linkProvider | Walter de Gruyter |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lc9MwEN6BdIZyKVDoECggZriqsWRbto8htARoeqCPyc2jxwoYEruT2NOBX8-qcUIpNzj5IFuW_a33oV1_C_DGmSKxWaa5R6M5aT_Sg1omHGUqMzIPUrqwoT85UePz5OM0nd74FyaUVTr8smh_NCuG1IGrbRs2yjZcA2SBB9bO5gSwDHnJSAy-NvPZXdjKAxNLD7aG798eXmxyCWQwr1usJHHClZKio278e5o_nMydq-t09WYtN6zO0QOw6_Wuik2-H7SNObA_b1E5_t8DPYSdzillw5UUPYI7WO3C9mjdC24X7k26FPxjmA7ZrL5is1BsxGrPRu-EuqyXjMS5tnT3JftWsdPh51M-qi-4ZKtqL3SsY3Cl8SXTbB7KghZhAjLNGDroPYHzo8Oz0Zh37Rn4JbkBDZeF98IgIimJ1EQ6C0fpvCmU0E5IktHIkgOfKERTGJ0bmUdWpyJOSWnEGO9Br6orfAossta7XDmVG58ob412HlE4g3FGIVnah_01MmX3jS1LCm3J7gbGsz683gzTiwkpD11h3dI5SSGKhELcqA_qFqK_ZwqBEIFQBhDKAEIZQKBQS8QiffavF76C7fHZ5Lg8_nDy6Tncl6EYJlJcpvvQaxYtviBvpjEvO3H9Bcez8MI |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BVipcChQqFgoYiau7sZM4yXHZdimPVojSqrfIjzFCbJPVJlHV_nrG3ewC5QanHJw4dr7JPDyfZgDeOFMkNss092g0J-1HelDLhKNMZUbmQUoXDvSPjtXhafLhPF2xCZueVunw26K7apcVUkeutl04KFvXGiALPLJ2dkEAy5CXjMRo7vxd2MgTEeUD2Bi_e3twtk4lkL286bCSxAlXSoq-cuPfs_zhY25d3mSr10v5zehMH4BZLXfJNfmx17Vmz17fquT4X_t5CFu9S8rGSxl6BHew2oZ7k1UnuG3YPOoT8I_hfMxm9SWbBaoRqz2b7As1rxtGwlxbennDvlfsZPzlhE_qMy7ZkuuFjvX1W2m8YZpdBFLQIkxAhhlD_7wncDo9-Do55H1zBj4nJ6DlsvBeGEQkFZGaSGfhKp03hRLaCUkSGlly3xOFaAqjcyPzyOpUxCmpjBjjHRhUdYVPgUXWepcrp3LjE-Wt0c4jCmcwziggS4ewuwKm7P-wpqTAlqxuqHc2hNfrYfowIeGhK6w7uicpREFCkUVDULcA_TVTCIMIgzJgUAYMyoABBVoiFumzf33wFWx-3p-Wn94ff3wO92VgwkSKy3QXBu2iwxfkyrTmZS-sPwECHu9p |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+low+level+of+CD16pos+monocytes+in+SARS-CoV-2+infected+patients+is+a+marker+of+severity&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Vasse%2C+Marc&rft.au=Zuber%2C+Benjamin&rft.au=Goubeau%2C+Laurie&rft.au=Ballester%2C+Marie-Christine&rft.date=2021-06-25&rft.pub=De+Gruyter&rft.issn=1434-6621&rft.eissn=1437-4331&rft.volume=59&rft.issue=7&rft.spage=1315&rft.epage=1322&rft_id=info:doi/10.1515%2Fcclm-2020-1801&rft.externalDBID=n%2Fa&rft.externalDocID=10_1515_cclm_2020_18015971315 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon |